Active Ingredient History
Tipifarnib is a farnesyltransferase inhibitor. Farnesyltransferase inhibitors block the activity of the farnesyltransferase enzyme by inhibiting prenylation of the CAAX tail motif, which ultimately prevents Ras from binding to the membrane, rendering it inactive. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Anemia, Refractory (Phase 1/Phase 2)
Astrocytoma (Phase 2)
Brain Neoplasms (Phase 2)
Breast Neoplasms (Phase 2)
Breast Neoplasms, Male (Phase 1/Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 2)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Chronic Disease (Phase 1/Phase 2)
Colorectal Neoplasms (Phase 2)
Ependymoma (Phase 2)
Glioblastoma (Phase 2)
Glioma (Phase 2)
Gliosarcoma (Phase 2)
Hepatoblastoma (Phase 2)
Histiocytosis, Langerhans-Cell (Phase 2)
Hodgkin Disease (Phase 2)
Inflammatory Breast Neoplasms (Phase 2)
Kidney Diseases (Phase 2)
Leukemia (Phase 2/Phase 3)
Leukemia, Eosinophilic, Acute (Phase 2)
Leukemia, Large Granular Lymphocytic (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia-Lymphoma, Adult T-Cell (Phase 2)
Leukemia, Monocytic, Acute (Phase 3)
Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1/Phase 2)
Leukemia, Myeloid, Acute (Phase 3)
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative (Phase 1/Phase 2)
Leukemia, Myelomonocytic, Acute (Phase 3)
Leukemia, Myelomonocytic, Chronic (Phase 2)
Leukemia, Myelomonocytic, Juvenile (Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 1)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large-Cell, Anaplastic (Phase 2)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Lymphoma, T-Cell (Phase 2)
Medulloblastoma (Phase 2)
Melanoma (Phase 2)
Multiple Myeloma (Phase 2)
Mutation (Phase 2)
Myelodysplastic Syndromes (Phase 3)
Myeloproliferative Disorders (Phase 1/Phase 2)
Neoplasms (Phase 2)
Neoplasms, Germ Cell and Embryonal (Phase 2)
Neuroblastoma (Phase 2)
Neuroectodermal Tumors (Phase 2)
Neurofibroma, Plexiform (Phase 2)
Neurofibromatosis 1 (Phase 2)
Oligodendroglioma (Phase 2)
Osteosarcoma (Phase 2)
Pancreatic Neoplasms (Phase 3)
Pheochromocytoma (Phase 2)
Polycythemia Vera (Phase 2)
Primary Myelofibrosis (Phase 2)
Prostatic Neoplasms (Phase 2)
Rhabdoid Tumor (Phase 2)
Rhabdomyosarcoma (Phase 2)
Sarcoma (Phase 2)
Sarcoma, Ewing (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Thrombocythemia, Essential (Phase 2)
Thrombocytopenia (Phase 1)
Thyroid Neoplasms (Phase 2)
Urinary Bladder Neoplasms (Phase 2)
Wilms Tumor (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue